CompletedPhase 1NCT06101173

A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

Studying Poliomyelitis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CanSino Biologics Inc.
Principal Investigator
Christina Chang, Dr
Nucleus Network Pty Ltd.
Intervention
Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)(biological)
Enrollment
72 target
Eligibility
18-54 years · All sexes
Timeline
2024 – 2024

Study locations (2)

Collaborators

Novotech (Australia) Pty Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06101173 on ClinicalTrials.gov

Other trials for Poliomyelitis

Additional recruiting or active studies for the same condition.

See all trials for Poliomyelitis →

← Back to all trials